<DOC>
	<DOCNO>NCT00249106</DOCNO>
	<brief_summary>The purpose study determine safety immune response investigational DNA Plasmid HIV vaccine , ADVAX e/g + ADVAX p/n-t ( ADVAX ) , three different dosage level , adult infect HIV .</brief_summary>
	<brief_title>Safety Immunogenicity Plasmid HIV Vaccine HIV Uninfected Adults</brief_title>
	<detailed_description>This dose escalation trial . Study site staff volunteer blind , blind apply assignment dose level ( low , middle high ) . Volunteers screen 42 day vaccination follow 18 month first vaccination . 15 volunteer randomize 4:1 ratio active vaccine placebo . Safety tolerability ADVAX e/g + ADVAX p/n-t investigational product evaluate least 14 day tenth volunteer lower dosage group receive second injection proceed nextdosage group .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , adult male female ; Age least 18 year day screen great 60 year day first vaccination ; Available follow plan duration study ( screen plus 18 month ) ; In opinion principal investigator designee , understood information provide . Written informed consent need give studyrelated procedure perform ; Willing undergo HIV test counseling , receive HIV test result ; If sexually active female , use effective method contraception screen least 4 month last vaccination , willing undergo urine pregnancy test . If sexually active male , willing use effective method contraception screen 4 month last vaccination . Clinically relevant abnormality history examination include history immunodeficiency use systemic corticosteroid , immunosuppressive , antiviral , anticancer , medication consider significant designated trial physician last 6 month ; Any acute chronic medical condition require care physician ( e.g. , , diabetes , coronary artery disease , rheumatologic illness , malignancy , substance abuse ) , opinion investigator , would preclude participation ; Any follow abnormal laboratory parameter moderate , severe , severe : haematology ( hemoglobin , absolute neutrophil count , absolute lymphocyte count , absolute CD4/CD8 count , platelet ) ; urinalysis , biochemistry ( total bilirubin , creatinine , AST , ALT ) . Volunteers mild laboratory abnormality judge principal investigator designee clinically significant may enrol . Reported high risk behaviour HIV infection , define : Had unprotected vaginal anal sex know HIV infect person casual partner ( i.e. , continue establish relationship ) within 6 month vaccination Engaged sex work money drug within 6 month vaccination Used injection drug ( illicit ) , Acquired STD within 6 month vaccination ; If female , pregnant planning pregnancy within 4 month last vaccination lactating ; Receipt blood transfusion blood product 6 month prior vaccination ; Receipt live attenuate vaccine ( influenza ) within 30 day vaccine within 14 day vaccination ; Participation another clinical trial investigational product currently within past 12 week expect participation study ; Receipt another experimental HIV vaccine time ; Infected HIV1 HIV2 indicate ELISA and/or RTPCR ; History severe local systemic reaction vaccination history severe allergic reaction ; Confirmed diagnosis hepatitis B ( surface antigen , HbsAg ) ; hepatitis C ( HCV antibody ) active syphillis ; History grandmal epilepsy , currently take antiepileptic ; In opinion investigator , unlikely comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>